Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy

Cancer

Volumn 109, Issue 3, 2007, Pages 536-541

  Sarosdy, Michael F ^a  

^a South Texas Urology and Urologic Oncology   (United States)

Author keywords

Brachytherapy; Hypogonadism; Prostate cancer; Testosterone replacement

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; EARLY CANCER; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SYMPTOMATOLOGY; TESTOSTERONE BLOOD LEVEL; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; GOSERELIN; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; LEUPROLIDE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 33846688614     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22438     Document Type: Article

References (25)

1. Huggins C, Hodges CV. The effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-297.
2. Klotz L. Combined androgen blockade: an update. Urol Clin North Am. 2006;33:161-166, v-vi.
3. Snyder PJ. Hypogonadism in elderly men-what to do until the evidence comes. N Engl J Med. 2004;350:440-442.
4. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172:920-922.
5. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005;173:533-536.
6. Fleming ID, Cooper JS, Hemson DE, et al., eds. AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven; 1998:219-222.
7. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
8. Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. Ten-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31-40.
9. Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:839-850.
10. Ragde H, Elgamal AA, Snow PB, et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer. 1998;83:989-1001.
11. Critz FA, Levinson AK, Williams WH, Holladay CT, Griffin VD, Holladay DA. Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy. J Urol. 1999;161:1199-1203.
12. Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta" ). Urology. 2005;66(5 suppl):83-94.
13. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol. 2002;167(2 pt 1):528-534.
14. Critz FA, Williams WH, Levinson AK, et al. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age. J Urol. 2003;170:1864-1867.
15. Akyol F, Ozyigit G, Selek U, Karabulut E. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone. Eur Urol. 2005;48:40-45.
16. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004 29:350:482-492.
17. Liverman CT, Blazer DG, eds. Testosterone and Aging: Clinical Research Directions. Washington, DC: National Academies Press; 2004.
18. Gaylis FD, Lin DW, Ignatoff JM, Amling CL, Tutrone RF, Cosgrove DJ. Prostate cancer in men using testosterone supplementation. J Urol. 2005;174:534-538.
19. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60:1451-1457.
20. El-Sakka AI, Hassoba HM, Elbakry AM, Hassan HA. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement. J Sex Med. 2005;2:235-240.
21. Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl. 2002;23:922-926.
22. Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003;170(6 pt 1):2348-2351.
23. Morgentaler A. Testosterone replacement therapy and prostate risks: where's the beef? Can J Urol. 2006;13(suppl 1):40-43.
24. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89:2085-2098.
25. Sarosdy MF, Schellhammer PF, Soloway MS, et al. Endocrine effects, efficacy, and tolerability of a 10.8-mg depot formulation of Zoladex (goserelin acetate) administered every 13 weeks to patients with advanced prostate cancer. BJU Int. 1999;83:801-806.